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Abstract
Autosomal recessive polycystic kidney disease (ARPKD)
results from mutations in the human PKHD1 gene. Both this
gene, and its mouse ortholog, Pkhd1, are primarily expressed
in renal and biliary ductal structures. The mouse protein
product, fibrocystin/polyductin complex (FPC), is a 445-kDa
protein encoded by a 67-exon transcript that spans >500 kb of
genomic DNA. In the current study, we observed multiple
alternatively spliced Pkhd1 transcripts that varied in size and
exon composition in embryonic mouse kidney, liver, and
placenta samples, as well as among adult mouse pancreas,
brain, heart, lung, testes, liver, and kidney. Using reverse
transcription PCR and RNASeq, we identified 22 novel
Pkhd1 kidney transcripts with unique exon junctions. Various
mechanisms of alternative splicing were observed, including
exon skipping, use of alternate acceptor/donor splice sites, and
inclusion of novel exons. Bioinformatic analyses identified,
and exon-trappingminigene experiments validated, consensus
binding sites for serine/arginine-rich proteins that modulate
alternative splicing. Using site-directed mutagenesis, we ex-
amined the functional importance of selected splice en-
hancers. In addition, we demonstrated that many of the novel
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transcripts were polysome bound, thus likely translated. Fi-
nally, we determined that the human PKHD1 R760H mis-
sense variant alters a splice enhancer motif that disrupts exon
splicing in vitro and is predicted to truncate the protein. Taken
together, these data provide evidence of the complex tran-
scriptional regulation of Pkhd1/PKHD1 and identified motifs
that regulate its splicing. Our studies indicate that Pkhd1/
PKHD1 transcription is modulated, in part by intragenic fac-
tors, suggesting that aberrant PKHD1 splicing represents an
unappreciated pathogenic mechanism in ARPKD.
Key messages
& Multiple mRNA transcripts are generated for Pkhd1 in
renal tissues
& Pkhd1 transcription is modulated by standard splice ele-
ments and effectors
& Mutations in splice motifs may alter splicing to generate
nonfunctional peptides
Keywords Autosomal recessive polycystic kidney disease .
PKHD1 . Alternative splicing . Exon splice enhancers
Introduction
Autosomal recessive polycystic kidney disease (ARPKD;
MIM 263200) is a hereditary hepato-renal fibrocystic disor-
der, with an estimated incidence of 1:20,000 live births [1].
Affected children typically present in utero with enlarged,
echogenic kidneys, and oligohydramnios due to poor fetal
urine output. An estimated 30–50 % of affected neonates die
shortly after birth as a result of severe pulmonary hypoplasia
and respiratory failure. Affected perinatal survivors have var-
ied clinical presentations. The principal causes of morbidity
and mortality in these children are systemic hypertension,
progressive renal insufficiency, and portal hypertension due
to portal tract fibrosis [2].
Mutations in the human gene, polycystic kidney and he-
patic disease 1 (PKHD1), cause all typical forms of ARPKD.
PKHD1 spans more than 469 kilobases (kb) of genomic
sequence and is predicted to include at least 86 exons, 71 of
which are nonoverlapping, and 15 appear to have alternative
splicing boundaries [3]. Mouse Pkhd1 is similar, extending
over 500 kbwith a minimum of 68 nonoverlapping exons, and
seven alternatively spliced exons [4]. The longest open read-
ing frame (ORF) of Pkhd1 contains 66 exons and encodes
full-length fibrocystin/polyductin complex (FPC), a protein of
4,059 amino acids [4]. FPC is predicted to have a long
extracellular N-terminus containing multiple Ig-like, plexin,
transcription factor (IPT), and parallel beta-helix (PbH1) re-
peats, a single transmembrane span, and a short cytoplasmic
C-terminus [4]. Human and mouse FPC share 73 % identity
over their complete length, though there are segments
with considerably higher (87 %) and lower levels
(40 %) of identity [4].
Multiple lines of evidence suggest that PKHD1/Pkhd1
are transcriptionally complex. Efforts to assemble the
complementary DNA (cDNA) of the longest PKHD1/
Pkhd1 transcript identified several distinct, smaller tran-
scripts [3]. Northern blot analysis of human tissues reveal
a complex signal [3], suggesting that Pkhd1 alternative
splicing may be organ/cell-type specific [4]. Interestingly,
a recent study by Bakeberg et al. [5] used a knock-in
strategy to generate an epitope-tagged version of the wild
type Pkhd1 allele. Their northern blot analysis identified
the full-length 13 kb band as well as three minor bands at
9, 7.7, and 7.5 kb. These variants are likely translated into
peptides, as demonstrated by various immunoblotting
studies, but the results have not been reproducible from
tissue to tissue or study to study [6–8]. Thus, FPC peptide
analysis has been hindered due to the lack of well-
validated immunoreagents.
Alternative splicing results in distinct messenger RNA
(mRNA) molecules comprised of different combinations of
exons and/or introns resulting in multiple structurally and
functionally distinct proteins [9]. It is estimated that 90 % of
human genes are alternatively spliced [10]. Both exons and
introns contain DNA binding sites called exonic/intronic
splicing enhancers (ESEs/ISEs) that are recognized by splic-
ing factors [11]. Members of the serine/arginine-rich splicing
factor family (SRSF) bind to splice enhancers and facilitate
spliceosome/mRNA interactions [12]. A subset of disease-
causing mutations are known to affect splicing, either by
directly altering canonical splice sites, or by disrupting SRSF
motifs [13–15].
Given that convergent lines of evidence suggest that
PKHD1/Pkhd1 undergoes extensive alternative splicing, we
characterized the kidney specific transcriptional profile of
Pkhd1 by cataloging its exon usage and examining key motifs
that regulate splicing. Our data indicate that Pkhd1/PKHD1
transcriptional processing is modulated in part by specific
SRSF intragenicmotifs. Furthermore, our analyses of reported
PKHD1 missense variants suggest that dysregulated PKHD1




The DBA/J2 mouse colonies were maintained at the Univer-
sity of Alabama at Birmingham (UAB) under protocols ap-
proved by the UAB Animal Care and Use Committee that is
fully accredited by the AAALAC.
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RT-PCR, subcloning, and sequencing
Total RNA from wild-type (WT), adult (2 months), and E18.5
embryonic tissues was prepared using the Qiagen RNeasy kit
(Qiagen, Valencia, CA, USA). cDNA was synthesized with
random hexamer primers using Invitrogen Super Script 3
cDNA synthesis kit (Life Technologies, Grand Island, NY,
USA). Long-range reverse transcription PCR (RT-PCR) was
performed using Roche’s Expand Long Template PCR system
(Roche, Indianapolis, IN, USA) with pooled RNA (N=5) for
isolation and characterization. Pkhd1 sequence specific
primers positioned in exons 1 and 67 were used to amplify
transcripts (Supplemental Table 1). The PCR products were
resolved on agarose gels, excised, and subcloned using
Invitrogen TOPO-TA 2.1 and XL PCR cloning kits (Life
Technologies, Grand Island, NY, USA). The constructs were
then evaluated by digestion, and representative clones were
sequenced. Pkhd1 exons specific primers (Supplemental
Table 5) flanking the putative novel splice sites were used for
both long-range RT-PCR and for the two-round PCR as indi-
cated. The sequence specificity of all primers was confirmed
using NCBI blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi) (see
Supplemental Tables 1 and 5).
Target enrichment and RNASeq studies
Custom enrichment was performed using a commercially
available Riva chip (Prognosys Biosciences, Inc., La Jolla,
CA, USA). Briefly, solution-based hybridization with Pkhd1
probes (Supplemental Table 2) selectively captured Pkhd1
cDNA for next-generation sequencing (Hudson Alpha Insti-
tute, Huntsville, AL, USA). From two separate experiments,
mouse inner medullary collecting duct (mIMCD3, ATCC
CRL-2123) total RNA was converted to cDNA, then
fragmented and hybridized with the custom Pkhd1 probes.
The targets were captured, amplified, and the cDNA was
sequenced on an Illumina HiSeq2000 (136 million 50 bp
pair-end reads). The RNASeq data (Supplemental Table 3)
were analyzed by the Biomedical Informatics Component of
the UAB Center for Clinical and Translational Science using
Tophat Galaxy (https://bitbucket.org/galaxy/galaxy-central/
src/tip/CITATION), and IGV [16, 17]. The Tophat analyses
files are located at the following server link: https://usegalaxy.
org/u/curtish-uab/h/boddu-et-al-2014-supplemental-table-3.
Bioinformatics analyses
The strength of all Pkhd1 splice sites was assessed using the
Splice Site Prediction byNeural Network (http://www.fruitfly.
org/seq_tools/splice.html) [18]. Analysis and comparison of
the exonic splice enhancers in Pkhd1 exons was performed
using the web-based algorithm ESE finder 3.0 (http://rulai.
cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home)
[19]. The ACESCAN2 Web Server was used to analyze
intronic splice enhancers [20].
Minigene experiments and site-directed mutagenesis
For exon-trapping minigene analysis, constructs containing
mouse Pkhd1 exons 6, 7, and either, 45 (negative control),
49, 51, or 52were generated in the exon-trapping vector pSPL3
[21]. For evaluating the R760Hmissense variant, either normal
or mutant PKHD1 exons 21, 22, and 23 were incorporated into
the vector. The genomic DNA included at least 200 bp of
intronic sequence flanking each exon. Total RNAwas purified
fromCOS cells 48 h post-transfection. cDNAwas generated by
reverse transcription using 4 μg of total RNA. Transcripts were
amplified by PCR and analyzed by sequencing. The vector
based primer sets used for PCR reaction were “a” (5-ATCTCA
GTGGTATTTGTGAGC-3) and “b” (5-TCTGAGTCACCT
GGACAACC-3). Site-directed mutagenesis was performed
using Stratagene QuikChange II XL Site-DirectedMutagenesis
Kit (Agilent Technologies, Santa Clara, CA, USA) according
to the manufacturer’s instructions.
Preparation of translated mRNA from polysomal fraction
and RT-PCR
Translationally active mRNA was prepared from the
polysomal fraction of adult WT kidney lysate using sucrose
gradient centrifugation as previously described [22]. mRNA
was separated, purified, and lithium chloride precipitated from
the bound polysomes. cDNA was synthesized with random
hexamer primers using Invitrogen Super Script 3 cDNA syn-
thesis kit, as above. Pkhd1 exon specific primer sets were used
for PCR (listed in Supplemental Tables 5 and 6). For sequenc-
ing, the amplicons were first subcloned using the Invitrogen
TOPO-TA 2.1 cloning kit (Life Technologies, Grand Island,
NY, USA), and sequenced.
Statistical analyses
For testing the over-representation of exon 6 skipping, we
used a binominal distribution to obtain p values assuming that
exon skipping started after every possible exon with equal
probability in each clone category. Statistical Software R was
used for these analyses.
Results
Pkhd1 transcripts vary by age and tissue
We developed and standardized a long-range RT-PCR proto-
col using primers within exon 1 and 67 to characterize the
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Pkhd1 transcriptional profile. Total RNA from wild-type
(WT) adult mouse kidney and liver, as well as from 18.5-
day-old embryonic kidney, liver, and placenta, were used as
templates for amplification (Fig. 1a). Multiple bands were
amplified in all samples, and several were excised and
sequenced (see below). Each lane represents samples from
five mice (n=3, 15 mice per organ), indicating the ubiq-
uity of these transcripts. To assess developmental patterns
of Pkhd1 splicing, we compared embryonic kidney, liver,
and placenta to adult kidney and liver (Fig. 1a). Neither
the kidney nor liver amplicon profiles from the embryonic
samples corresponded to the adult samples. To examine
differences among adult tissues we compared WT pancre-
as, brain, heart, lung, testes, liver, and kidney. Unique sets
of transcripts were also observed in each of these adult
tissues (Fig. 1b), suggesting tissue-specific transcription.
These results suggest that Pkhd1 is differentially spliced
in an age and tissue-specific fashion.
Kidney-specific Pkhd1 transcripts
To validate these results and determine the exon composition
of each amplicon, we isolated and subcloned the 2.5, 4.5, and
6.5 kb bands amplified fromWTkidney cDNA (Fig. 1a’). The
full-length mRNA containing 67 exons (>12 kb) was used as a
reference [4]. Because each band likely represented multiple
transcripts, restriction fingerprinting was performed using
EcoRI, PstI, and SacI restriction endonucleases. The clones
were grouped based on their band patterns (Fig. 2, “N”) and
representative clones were sequenced, resulting in a catalog of
22 unique Pkhd1 transcripts (Fig. 2). A variety of alternative
splicing mechanisms were observed including exon skipping,
which generated 19 novel exon junctions; two novel inclu-
sions of intronic sequences (Fig. 2 represented as asterisk);
and transcripts resulting from alternative exon acceptor and
donor site usage (Fig. 2, yellow boxes). The predominant
skipping event occurred at exon 6. Indeed, exon 6 usage
Fig. 1 Expression of
alternatively spliced Pkhd1
variants in various fetal and adult
mouse tissues. a RT-PCR
comparing the amplicons from
kidney, liver, and placenta from
WT 18.5 dpc embryos compared
to adult kidney and liver.
Transcripts shown in the box are
those represented in a’. a’
Representative image of the
predominant kidney bands (from
box in A) isolated, cloned, and
sequenced. b Representative RT-
PCR gel image comparing
amplicons from adult WT mouse
pancreas, brain, heart, lung, testes,
liver, and kidney using long range
RT-PCR with primers positioned
with exons 1 and 67 of the longest
ORF of Pkhd1. RT-PCR for each
tissue sample was performed in
triplicate. Beta-actin serves as an
input loading control and Prkdc is
shown to demonstrate the
integrity of large size RNA (9 kb);
NTC no template control. No
amplification products were seen
in the no-reverse transcriptase
(−RT) controls (data not shown)
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(e.g., 6–49, 6–51, 6–52, etc.) was significantly more frequent
than would be predicted to occur randomly (p<1.4e−61).
Further, 14/22 were predicted to use the canonical translation
start site (TSS) in exon 2 (Fig. 2, green boxes) and maintained
frame through the novel splice junction. NCBI ORF finder
(http://www.ncbi.nlm.nih.gov/gorf/gorf.html) predicted
alternative TSSs, normally downstream of the splice
junction within the WT frame, for the clones whose frame
was not maintained due to splicing. For example, clone 2.5–2,
has a junction between exons 4–61, which causes a
misalignment of the WT frame. NCBI ORF finder, however,
predicts that the first ATG within exon 61 is the TSS resulting
in a truncated, yet wild-type peptide.
We next validated our results by assessing the presence of
these novel exon junctions in mIMCD3 cells, representing the
nephron segment most significantly involved in the ARPKD
phenotype. The initial template was generated by long-range
RT-PCR, followed by a second PCR round that amplified 15/
19 of our splice variants (indicated with a "Y", Fig. 2). Taken
together, these data indicate that the survey of amplicons
identified by RT-PCR are alternative Pkhd1 transcripts
expressed in renal epithelia.
RNASeq confirms alternative Pkhd1 transcripts
We next sought to generate a more inclusive list of Pkhd1
exon junction usage. Using high-throughput RNA sequencing
(RNASeq) we evaluated Phkd1 transcripts. In initial studies,
we utilized standard global RNASeq methods to evaluate
exon junctions using WT kidney RNA. However, this initial
dataset had too few reads to be reproducible or significant.
Therefore, we developed a target enrichment strategy using
mIMCD3 RNA (see “Methods and materials”) in which
cDNA corresponding to Pkhd1 was enriched before sequenc-
ing (Supplemental Table 2). We performed the analyses in
duplicate. At least 275 unique exon–exon junctions were
identified, each of which was identified hundreds or thousands
of times (Supplemental Table 3, bold). Among these unique
junctions, 20 variants from our RT-PCR catalog were con-
firmed by RNAseq (Fig. 2). These RNASeq data validate our
focused approach and underscore the variability in Pkhd1
splicing.
Bioinformatics analysis of exon and intron splicing motifs
To begin exploring the mechanisms that modulate the splicing
of Pkhd1, we used informatic tools. ESE Finder 3 (http://rulai.
cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home)
identifies putative ESEs associated with common serine/
arginine-rich splicing factors (Supplemental Table 4). We
analyzed each of the 67 Pkhd1 exons for ESEs (data not
shown). For exons that were commonly involved in alterna-
tive splicing based on our catalog (4, 6, 36, 37, and 42), we
compared the donor/acceptor scores as well as the SRSF
Fig. 2 Kidney specificPkhd1 splice variants catalog. The plasmid library
generated consisted of 22 Pkhd1 alternatively spliced amplicons. The
alternative splicing events included exon skipping; two novel exon in-
clusions (*) of 104 bp (IVS 46) and 123 bp (IVS 55); and transcripts with
truncated exons due to the utilization of cryptic acceptor sites (yellow
boxes). Each of the 22 putative transcripts appeared to encode amino-acid
sequences in the same frame as the WT peptide, 14 using the canonical
translation start site in exon two. Predicted translation start sites indicated
by green boxes. Nineteen variants were re-evaluated and amplified from
WT kidney RNA using junction specific primers (clones 6.5–12, −13,
and −14 not screened); 15 of these junctions were also found in mIMCD3
cDNA and are indicated by “Y.”Where multiple changes were observed
in any one transcript (inclusion of IVS::asterisks and hybrid
exons::yellow boxes) if both were validated in the mIMCD3 cDNA there
is a second “Y”. Many of the novel junctions were also identified in our
RNASeq data (Supplemental Table 1); the number of times each junction
was found is indicated.NNumber of times each clone was found (of total
50 clones per MW band); asterisk novel exon from an IVS; green boxes
predicted translation start site; yellow boxes exon partially spliced out
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motifs to assess why certain Pkhd1 exons are more frequently
involved in long range splicing events than others. In evalu-
ating the donormotifs, we compared each exon’s splice donor
site to that of exon 6, which we found to be the most common
donor exon in our catalog (Fig. 3a). We identified ESEs at the
3′ end of exons 4 and 6 (Fig. 3a, arrows), but there are none
within the last several nucleotides of exon 7 (Fig. 3a, no
arrow), perhaps explaining why the 4 and 6 are commonly
involved in long-range splicing events (Fig. 2, 17/22). We
then compared the number of ESEs at the 5′ end of exons and
their predicted acceptor scores. We compared exons 36, 37,
and 42, which were common splice acceptors (spliced to at
least three times), exons 49, 51, and 52, which had 3′ SRSF5
motifs (Fig. 3b arrows) to exon 7, a poor acceptor. Interest-
ingly, while exons 36, 37, and 42 lacked any notable 5′ ESEs,
their splice prediction scores were quite high (Fig. 3b, ≤0.92).
Fig. 3 Characterization of specific exonic signatures of Pkhd1. a Repre-
sentative donor site analysis of exons 4, 6, and 7 predicts various SR
motifs (bars) throughout the exon. The exon sequence is represented
along the X-axis. The height of the bars represents the motif scores; the
width of the bars indicates the length of the motif. SSPNN [18] analysis
was used to predict the donor scores, as indicated. b Representative
acceptor analysis of exons 7, 36, 37, 42, 49, 51, and 52 predicts various
SRSF/SR motifs as above. The SSPNN values are indicated. The algo-
rithm did not identify a splice acceptor in exon 7. The number of times
each of the acceptor exonswas spliced to exon 6, as revealed byRNASeq,
is indicated. Arrows indicate the presence of a strong motif at the 3′
(donor) or 5′ (acceptor) end of a given exon
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Exons 49, 51, and 52, which had lower splice acceptor scores
(≥0.9), each had ESEs at their 5′ ends (Fig. 3b, arrows). Taken
together, these data suggest that for splicing to occur, an
acceptor/donor site must either has a ESEs or have high
predicted strength. Exons that lack both, e.g., exon 7, appear
to be infrequently involved in alternative splicing.
The polypyrimidine tract (PT) is another important cis-acting
element that impacts splicing [23]. The PT consensus sequence
(Fig. 4a, top, bold) is loosely defined as a series of >15 thymine
bases immediately upstream of the intervening sequence (IVS).
A strong PT is predicted to contain multiple pyrimidines and
ISE motifs, whereas a PT that is interrupted by purine residues
and lacks any ISEs is a weak acceptor motif [24]. Alignment of
several Pkhd1 PTs illustrates that IVS6 is a poor splice acceptor
motif with only eight thymine bases and several purine residues
(Fig. 4a, IVS6). Conversely, IVS50 has a very strong PTwith 16
thymine residues (Fig. 4a). We then assessed the intronic seg-
ments upstream of the acceptor site using ACESCAN2 [25].
The alignment reveals that IVS6 contains only three ISEs within
its polypyrimidine tract, while IVS48 has 15; IVS50 has 13; and
IVS51 has 13 (Fig. 4b). Together, these data suggest that several
canonical exon and intron splicing motifs are contained within
Pkhd1, and these motifs regulate the generation of many alter-
native mRNA molecules.
Minigene exon-trapping studies to evaluate exon and intron
splicing motifs
To assess the functional importance of the identified intragenic
motifs in Pkhd1 splicing, we used minigene constructs in exon-
trapping studies. The minigene constructs contained Pkhd1
exons 6, 7, and either 49, 51, or 52 (Fig. 5a). We first charac-
terized the canonical splice variants with constructs containing
WTexons 6–7–49, 6–7–51, and 6–7–52 (Fig. 5a, b, products 1,
4, and 6, respectively). Alternative splicing events, mostly the
skipping of exon 7, were observed (Fig. 5b, products 2, 5, and
7). Surprisingly, there was a minor product that included 98 bp
of IVS51 downstream of exon 51 (Fig. 5b, product 3, caret),
apparently resulting from a cryptic donor site. As a negative
control, we used aminigene construct containing exons 6, 7, and
45. Importantly, exon 45 is not predicted to have any SRSF5
motifs, has a weak PT, and was not observed among the alter-
natively spliced products in our catalog (Fig. 2). No exon splice
products containing exon 45 were detected (data not shown).
To examine the influence of SRSF5 motifs, we used site-
directed mutagenesis to generate a Pkhd1 exon 51 with an
ablated SRSF motif (51MUT ESE, Fig. 6a, asterisk). The WT
and 51MUT ESE constructs had two splice products in common
(Fig. 6a, products 1 and 2). However, splicing to generate 6–51
was not observed from the 51MUT ESE vector (Fig. 6a, product 3
absent from 51MUT ESE lane). Interestingly, the 51MUT ESE
construct yielded a product without exon 51 that was not found
in the WT experiment (Fig. 6a, product 4). The most common
product produced from the 51MUT ESE vector was the canonical
transcript, suggesting that the exon 51 SRSF5 motif may not be
necessary for canonical splicing and rather may be important in
alternative transcript generation.
We then evaluated the functional significance of ISEs and
the PTs as detailed in Fig. 4, using site-directed mutagenesis to
alter IVS50, immediately preceding exon 51. The WT IVS50
sequence, with 13 predicted ISEs (Fig. 4b) and a strong PT,
was replaced with a random sequence that did not contain any
ISEs and had few pyrimidine residues disrupting the acceptor
site (CACATTCGGAGTTTGAGCT; 51RAND, Fig. 6b). The
WT minigene construct yielded three products, each contain-
ing exon 51 (Fig. 6b products 1, 2, 3). In contrast, none of the
Fig. 4 Characterization of the
polypyrimidine signatures in
Pkhd1 introns. aAlignment of the
polypyrimidine tracts (PT), 24 bp
upstream of the indicated exons
compared to the consensus
sequence (top, bold). Analysis
shows that the PT in IVS6
contains more purines and fewer
pyrimidines as compared to any
other IVS. The tally of thymine
residues is indicated in the #T
column. b Analyses of the
intronic splice enhancers just
upstream of the acceptor site of




51RAND products contained exon 51 indicating that IVS51
was not appropriately recognized as an acceptor motif
(Fig. 6b, products 4 and 5). Finally, we replaced IVS50 with
the less strong IVS6 acceptor region, which is predicted to
have only three ISEs and a weak PT (GAGCTAACTCTTCT
TAAAA; 51IVS6, Fig. 6c). The 51IVS6 construct produced only
the canonical product (Fig. 6c, product 2). These data validate
our bioinformatic predictions, confirm the functionality of
these specific intragenic motifs in vitro, and suggest that the
PT, SRSF motifs, and additional ISE sites function primarily
to enhance alternative splicing events.
Pkhd1 polysome-bound mRNAs
We have demonstrated that alternative Pkhd1 transcripts exist in
various mouse organs and mIMCD3 cells; however, whether
these transcripts are translated into proteins remains to be con-
firmed. Unfortunately, with no thoroughly characterized and
validated antibodies, immunoblotting has been inconclusive.
Thus, we used the association of Pkhd1 mRNAs with poly-
somes as a surrogate assay. Upon isolation of mRNA::polysome
complexes from kidney tissue we evaluated those mRNAs for
Pkhd1-specific isoforms (Supplemental Table 5 and 6). The
integrity of the isolated polysome RNA was confirmed using
primers for the Ywhaz andGapdh genes, a beta-actin primer set
was used to check for genomic DNA contamination, and
primers for the h19 noncoding RNA were used as a negative
control for total RNA contamination (Fig. 7a, lanes 1–8). Primer
pairs flanking the Pkhd1 canonical exon junction 6–7 readily
amplified the appropriate product with standard PCR (Fig. 7b
lane 9). However, standard PCR did not amplify the other
variants, suggesting again that the alternatively spliced tran-
scripts are expressed at low levels. Using two-round, nested
PCR on the isolated polysome RNA, we successfully amplified
products corresponding to exon junctions 4–49, 6–38, 6–51, 6–
52, and 6–61 (Fig. 7b, lanes 11, 13, 15, 17, and 19). All of the
amplicons were sequence verified. As an additional negative
control, we used exon junction 6–45 primers as above and no
amplification products were identified (data not shown). These
data indicate that a subset of Pkhd1 alternative transcripts are
polysome bound and are likely translated into peptides.
PKHD1 missense variant (R760H) shows splicing defects
Our data demonstrate that Pkhd1 is transcriptionally complex
and the identified SRSF motifs, ISEs, and PTs are functionally
important in alternative splicing. Therefore, we evaluated the
Aachen Mutation Database for ARPKD (http://www.humgen.
rwth-aachen.de) [26], as well as data from the UAB Medical
Genomics Laboratory to identify patients with lesions that may
have altered an SRSF splicing motif. One particular variant,
R760H (c.2279G>A) with a single nucleotide change in
PKHD1 exon 22, is of indeterminate pathogenicity and
abolishes a 3′ SRSF5 motif in a region sparsely populated by
ESEs (Fig. 8a). We again used minigene exon-trapping exper-
iments to assess the effect of the R760H variant on PKHD1
splicing. The minigene construct with the normal sequence
exclusively yielded a product of 706 bp with PKHD1 exons
21, 22, and 23 (Fig. 8c; WT/1), whereas the R760H minigene
generated a single product skipping exon 22 (Fig. 8c; Mut/2).
This exon skipping event is predicted to cause a pathogenic
frameshift, p.V279X (Fig. 8d). These data suggest that the
enhancer motifs within exon 22 of the PKHD1 gene are
functional and critical for proper splicing in vitro.
Discussion
Several lines of evidence indicate that Pkhd1/PKHD1 is tran-
scriptionally complex. However, it is not understood how
extensively Pkhd1/PKHD1 mRNA is processed or what gov-
erns the generation of alternative transcripts. The current study
was designed to address this question using RT-PCR and
RNASeq. We noted age- and tissue-specific differences in
Fig. 5 Evaluation of exon and intron signatures in Pkhd1. a For exon-
trapping studies, minigene constructs containing mouse Pkhd1 exons 6,
7, and 49, 51, or 52 with 200 bp of flanking intronic sequences (shown as
dashed lines) were cloned into the pSPL3 vector and transfected into
COS7 cells. b Representative RT-PCR amplicons demonstrating the
various splicing events is shown. Each reaction showed that exon 7 was
skipped frequently (products 2, 5, and 7). In addition, there was a faint
product 3, which included a 98-bp of Pkhd1 IVS51 indicated by caret. a,
b pSPL3 vector exons
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mRNA profiles, and we identified several alternative Pkhd1
transcripts. We then identified multiple splice enhancer motifs
predicted to modulate Pkhd1 splicing and demonstrated their
importance using site-directed mutagenesis. Unfortunately,
given the paucity of reliable immunoreagents to endogenous
FPC, we could not validate these isoforms by immunoblot-
ting. Thus, as a surrogate, we analyzed polysome-bound
mRNAs and inferred that many of our unique transcripts are
likely translated.
There are several implications of this transcriptional com-
plexity. First, the large size and transcriptional complexity of
Pkhd1 would be predicted to complicate standard gene-
targeting strategies and RNA-interference-based approaches.
For example, Williams et al. [27] generated a Pkhd1lacZ/lacZ
mouse that carries a lacZ reporter cassette replacing Pkhd1
exons 1–3. They reported that homozygous mutant mice were
viable, but progressively developed cysts. In their study, RT-
PCR yielded amplicons only in the wild-type and heterozy-
gous mice, prompting the authors to conclude that the lacZ
insertion generated a null allele. In collaboration with the
Igarashi lab, we performed long-range RT-PCR and identified
alternative Pkhd1 products in the Pkhd1lacZ/lacZ kidneys
Fig. 6 Evaluation of mutated
splicing elements in Pkhd1. a
Site-directed mutagenesis of
Pkhd1 exon 51 (A>G indicated
by an asterisk and labeled 51MUT
ESE) removed the predicted 5′
SRSF5 motif. WT exon 51 and
51MUT ESE produce two common
products (products 1 and 2). The
51MUT ESE construct did not skip
exon 7, but did yield a product
without exon 51 (compare
products 3 and 4). b Site-directed
mutagenesis replaced Pkhd1 WT
IVS50 with a random sequence
51RAND that did not include any
ISE/PT elements. Exon-trapping
experiments revealed that the WT
construct yielded three products
(products 1, 2, and 3); whereas
with the 51RAND minigene
construct, none of the products
contained exon 51. c Site-directed
mutagenesis replaced WT Pkhd1
IVS50 with Pkhd1 IVS6 to
generate a 51IVS6 minigene
construct. The WT construct
yielded three alternatively spliced
products (products 1, 2, and 3);
whereas only the canonical
product was observed for the
51IVS6 construct. Caret indicates
the inclusion of 98 bp from IVS51
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(Supplemental Figure 1, yellow boxes, sequence confirmed).
These data suggest that alternative isoforms may compensate
for sequence variants and small insertions/deletions, at least in
the kidney. It is important to note that, of the Pkhd1 mouse
models generated to date, all have a significant liver pheno-
type, but the renal phenotype is either absent or remarkably
less severe than in the human disease. Together, these data
suggest tissue-specific tolerability of isoform loss. Notably, our
data indicate that there are fewer isoforms in the liver, possibly
making the liver more susceptible to loss of specific Pkhd1
transcripts. A more complete understanding of Pkhd1 tran-
scriptional complexity will be required for proper interpreta-
tion of mouse model phenotypes and tissue specific functions.
Second, the complex transcriptome may explain the incon-
sistent data that have been reported regarding the detection of
smaller Pkhd1 isoforms in multiple gene-targeted models and
the variability in FPC detection using the available
immunoreagents [6–8]. Despite data variability, several lines
of investigation are beginning to support our thesis of Pkhd1
transcriptional complexity. For example, the atlas generated by
the Genitourinary Development Molecular Anatomy Project
(GUDMAP; http://www.gudmap.org/Menu_Index/Gene_
Expression.html) [28] contains a transcript present in our
catalog (clone 4.5–4; novel splice junction 4–49, 435
RNASeq reads). In addition, northern blot analysis in
kidneys engineered by Bakeberg et al., to express an
epitope-tagged version of the wild-type Pkhd1 allele, identi-
fied the full-length 13 kb band, as well as three minor bands
at 9, 7.7, and 7.5 kb. These data are consistent with ours and
support the interpretation that Pkhd1 primarily encodes the
full-length transcript, with these alternative-spliced transcripts
comprising a minority of the transcriptome. With our alter-
native approaches (e.g., two round PCR and RNASeq), we
were able to isolate and characterize some of the less fre-
quent transcripts noted by Bakeberg et al. [5] and others
[29–31].
In human ARPKD, the mechanisms by which PKHD1
mutations cause clinical disease are not well understood.
Review of the Aachen Mutation Database for ARPKD
(http://www.humgen.rwth-aachen.de) [26] reveals that
∼44 % of potentially mutant alleles involve missense
changes [4, 32]. Most patients are compound heterozygotes,
and the functional effect of any particular mutant allele can be
difficult to discern. Nevertheless, some broad themes have
emerged. Notably, patients with two truncating mutations
typically have a severe phenotype leading to perinatal
demise (reviewed in [33]). However, there are notable
exceptions, e.g., a child who is homozygous for a large
PKHD1 deletion surviving well past the neonatal period
[34]. Moreover, not all missense mutations lead to a more
benign outcome; indeed, a number of missense mutations
result in severe phenotypes when present with a truncating
mutation in trans or in the homozygous state [33]. We believe
that our data indicate that the fidelity of transcriptional
splicing requires the integrity of both canonical splice sites
as well as ESE motifs. Our R760H analyses serve as a proof-
of-concept of this point. Based on these data, we suggest that
single nucleotide changes at the 5′ or 3′ ends of an exon
(within ∼20 bp) should be examined, not only for the impact
on a specific amino acid residue but also potential effects on a
conserved ESE motifs/splicing.
Many of these single nucleotide variants involve SRSF
binding sites and would likely impact splicing (Supplemental
Table 4). In support of this thesis, our in vitro assay of the
R760H variant of exon 22 did not yield an exon 22-containing
amplicon and causes an exon skipping event that leads to a
Fig. 7 Polysome-bound Pkhd1 mRNAs. a The integrity of the poly-
some-bound kidney mRNAwas confirmed using primers for Ywhaz and
Gapdh; the beta-actin primer set was used to check for genomic DNA
contamination, the genomic product includes an intron and thus, is larger
(indicated by asterisk, mRNA indicated by less than sign). As a negative
control, two round PCR was performed on the h19 gene, a non-coding
RNA. Total kidney RNA was used as a control for the h19 gene PCR
reaction (lanes 5–8). b RT-PCR from isolated polysome RNA corre-
sponding to exon junctions 6–7, 4–49, 6–38, 6–51, 6–52, and 6–61. All
the amplified products were sequence confirmed, and plasmid DNAwas
used as a control. Primers and sequences listed in Supplemental Table 5
and 6. Where indicated, two round PCR was conducted
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frame shift mutation. Importantly, exon 22 has only two SRSF
sites allowing for a straightforward experimental approach,
wherein compensation by multiple overlapping sites was un-
likely. Analysis of conservation of R760 reveals that only the
human and chimp share this amino acid (data not shown).
More importantly, however, SRSF analysis in human, chimp,
mouse, dog, cat, horse, cow, and sheep reveals that each of
these animals has an SRSF5 motif within the last 10 bases of
the corresponding exon. Therefore, we speculate that, while
the R760H amino acid substitution may have marginal path-
ogenic significance (as predicted by SIFT), the associated
change in a highly conserved SRSF5 motif may represent
the actual the pathogenic change. This experiment provides
a proof of concept and supports the hypothesis that defects in
PKHD1 splicing regulation may contribute to the pathogene-
sis of ARPKD.
In summary, our RT-PCR-based transcript library,
RNASeq data, and polysome experiments provide convergent
lines of evidence that Pkhd1 is transcriptionally complex, with
the full-length transcript being the most highly expressed.
Although expressed at lower levels, alternative transcripts
need to be considered when designing experiments to dissect
the role of FPC, as well as in assessing the impact of missense
variants in ARPKD pathogenesis.
Fig. 8 PKHD1 missense variant R760H is inefficiently spliced. a ESE
Finder 3 analyses identified an SRSF5 motif in the 3′ end of WT PKHD1
exon 22, while analysis of the R760H variant revealed loss of the motif.
The nucleotides are indicated along the X-axis, whereas the Y-axis repre-
sents the strength of the SRSF5 motifs; SSPNN donor scores are listed. b
WTor R760H minigene constructs containing human PKHD1 exons 21,
22, and 23 with 200 bp of flanking intronic sequences were cloned into
pSPL3 vector (mutation indicated by R760H). c Representative RT-PCR
results are shown. The WT minigene yielded only the canonical 706 bp
PKHD1 product containing exons 21, 22, and 23 (WT lane, product 1).
The mutant construct (asterisk) generated a product of 567 bp due to
skipping of exon 22 (Mut lane, product 2). The empty vector was used as
a control (Vect lane, product 3). d Translation of the wild-type and mutant
peptide sequences is shown. With the skipping of exon 22, the predicted
exon 21–23 junction results in a frame shift that leads to a premature stop
codon (number sign). a, b Vector specific exons. All amplified products
were sequence confirmed
J Mol Med
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